1Simeonov SB, Botushanov NP, lliev DA, et al .Amaryl (glimepiride) in patients with type 2 diabetes mellitus Folia.Med (Plovdiv), 2002,44( 3 ) : 15-- 9.
2Charpentier G,Vaur L,Halimi S, et al .Predictor of response to glimepiride in patients with type 2 diabetes mellitus.Diabet Metab, 2001,27(5-C1) :563--71.
3Lawrence CL, Rainbow RD, Davies NW, et al .Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels .Br J Pharmacol, 2002,136(5) :746-52.
4Hu S.Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.Eur J Pharmacol, 2002,442(1-2) : 163- 71.
5Overkamp D, Volk A, Maerker E, et al.Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care, 2002,25 ( 11 ) : 2065-- 73.
6Muller G, Hanekop N, Wied S, et al .Cholesterol depletion blocks redistribution of lipid raft components and insulin-mimetic signaling by glimepiride and phosphoinositolglycans in rat adipocytes .Mol Med, 2002,8(3) : 120-- 36.
